Acute myeloid leukemia is a cancer of the blood and bone marrow that progresses quickly and affects the production of normal blood cells. It is one of the major subtypes of acute leukemia and primarily affects adults and older adults.
New research highlights strategies to overcome cancer drug resistance: a triple-drug AML combination, a breast cancer resistance target, evolutionary treatment switching, DNA damage mechanisms, and sildenafil's anti-metastatic potential.
The FDA approved Tregzi (Orca-T), a first-of-its-kind regulatory T cell-based immunotherapy, for adults with blood cancers undergoing matched donor stem cell transplants. Approval was based on the PRECISION-T trial, in which 78% of treated patients achieved chronic GVHD-free survival at one year versus 38.4% with standard transplant.
A CML blast phase prognostic score separates patients into three risk groups with distinct survival. Separate AML studies identified circRNA and NFS1/GSDMD biomarkers; a T-ALL study highlighted markers including CD38, CD99, and TRBC1.
A rare BTK A428D mutation causes resistance to all BTK-targeted therapies, finds a new study. China is reviewing the first CAR-T therapy for gastric cancer, and research reveals why BET inhibitors fail and targets AML's DNMT3A mutation.
The FDA approved Orca-T (Tregzi) for matched donor hematopoietic stem cell transplantation in adults with hematologic malignancies. Phase 3 Precision-T data showed reduced graft-versus-host disease across leukemia and MDS populations, with experts calling it a 'big advance' requiring further comparison with post-transplant cyclophosphamide.
Kura Oncology's ziftomenib shows 96% complete response in frontline AML and $5.8M in early commercial sales; updated FIT-001 trial data for kidney cancer to be presented at 2026 summit; analysts see significant upside with an average target of $32.45.
New CAR T-cell data show 100% MRD negativity in high-risk smoldering multiple myeloma, a novel CAR T approach for AML, and a new T-cell pathway, while a case report warns of a rare therapy-related complication.
Cantargia reported full year 2025 financial results with net sales of SEK 316.7 million and cash of SEK 281.8 million. The company secured a SEK 124 million financing package to advance clinical development of nadunolimab, including a phase Ib study combining it with a RAS inhibitor in pancreatic cancer.
Updated KOMET-007 trial data show ziftomenib plus chemotherapy achieves 94% twelve-month overall survival in newly diagnosed NPM1-mutant AML. The oral menin inhibitor, approved by the FDA in November 2025 for relapsed/refractory disease, is being evaluated in a Japanese Phase II trial and a global Phase 3 study.
Two separate clinical trials have reported advances in cancer care. An oral drug combination of decitabine-cedazuridine and venetoclax showed efficacy in older patients with acute myeloid leukemia, with a 47% complete response rate in a phase 2b trial. A separate randomized controlled trial found that delaying pegfilgrastim administration to 72 hours post-chemotherapy significantly reduced bone pain in women with stage I–III breast cancer.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07773909 |
Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive Chemotherapy |
COMPLETED | PHASE4 |
| NCT07770698 |
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07763054 |
Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients |
RECRUITING | |
| NCT07758218 |
Allogeneic iNKT Cell Therapy (agenT-797) After SCT |
NOT_YET_RECRUITING | PHASE1 |
| NCT07755202 |
Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia |
NOT_YET_RECRUITING | PHASE2 |
| NCT07751588 |
Plasma ctDNA Monitoring in Pediatric Acute Leukemia |
NOT_YET_RECRUITING | |
| NCT07749976 |
GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07743112 |
A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia |
RECRUITING | PHASE2 |
| NCT07743047 |
Harnessing the Immunosuppressive Leukemic Microenvironment to Engineer T Cells With Enhanced Anti-tumor Functionality |
NOT_YET_RECRUITING | |
| NCT07737769 |
Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome |
NOT_YET_RECRUITING | PHASE1 |
